Floatz logo

ACOLBIFENE

Breast Ductal Carcinoma In Situ

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Breast Ductal Carcinoma In Situ cohort.

Asset / SponsorPhaseRating
ROPIVACAINE
Zealand University Hospital
Phase 4BB
SUFENTANYL
Zealand University Hospital
Phase 4BB
TAMOXIFEN
Northwestern University
Phase 3BB
Metformin
M.D. Anderson Cancer Center
Phase 3BB
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

ACOLBIFENE is also rated in:

breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
lobular breast carcinoma in situDormant
CCC
Indicative ·
53 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →